<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Algernon Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc</link>
<description>Latest news and press releases for Algernon Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 15 Apr 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/algernon-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<item>
<title>Algernon Health Announces Effective Date of Previously Announced Name Change to “Grey Matters Health Inc.” and its 10:1 Share Consolidation</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-health-announces-effective-date-of-previously-announced-name-change-to-grey-matters-health-inc-and-its-101-share-consolidation</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-health-announces-effective-date-of-previously-announced-name-change-to-grey-matters-health-inc-and-its-101-share-consolidation</guid>
<pubDate>Wed, 15 Apr 2026 20:01:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, April 15, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces that effective April 21, 2026 its corporate name will change from “Algernon Health Inc.” to “Grey Matters Health Inc.” and the Company will consolidate its Class A common shares (the “Common Shares”) on a ten (10) to one (1) basis (the “Consolidation”) as previously announced on March 31, 2026. The</description>
</item>
<item>
<title>Algernon Health Announces Proposed Name Change to “Grey Matters Health Inc.” and a 10:1 Share Consolidation</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-health-announces-proposed-name-change-to-grey-matters-health-inc-and-a-101-share-consolidation-2</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-health-announces-proposed-name-change-to-grey-matters-health-inc-and-a-101-share-consolidation-2</guid>
<pubDate>Tue, 31 Mar 2026 23:09:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces that it intends to change its corporate name from “Algernon Health Inc.” to “Grey Matters Health Inc.” (the “Name Change”). The Company has reserved the new name and new symbol “GREY” with the Canadian Securities Exchange (the “CSE”). The new symbols for the OTCQB and Frankfurt exchange will be pro</description>
</item>
<item>
<title>Algernon Health Announces NOVASCAN NEUROIMAGING CLINICS™ as the New Brand Name for its U.S. Brain PET Scanning Centers</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-health-announces-novascan-neuroimaging-clinicstm-as-the-new-brand-name-for-its-us-brain-pet-scanning-centers</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-health-announces-novascan-neuroimaging-clinicstm-as-the-new-brand-name-for-its-us-brain-pet-scanning-centers</guid>
<pubDate>Wed, 25 Mar 2026 11:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to introduce NovaScan Neuroimaging ClinicsTM as the new brand name and visual identity for its planned U.S. network of brain PET scanning centers being launched at the HCA Florida University Medical Offices building in Davie, and featuring the U.S. FDA-cleared CareMiBrain™ system, a groundbreaking, standalone PET scanner withou</description>
</item>
<item>
<title>Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-to-open-the-first-brain-dedicated-pet-scanning-clinic-in-the-us-at-the-hca-florida-university-medical-office-building</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-to-open-the-first-brain-dedicated-pet-scanning-clinic-in-the-us-at-the-hca-florida-university-medical-office-building</guid>
<pubDate>Mon, 23 Mar 2026 11:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to announce that it will be opening its inaugural brain PET (Positron Emission Tomography) scanning clinic at the HCA Florida University Medical Office Building in Davie, located on the campus of the HCA Florida University Hospital. Algernon USA LLC, a wholly owned subsidiary, has signed a five-year lease with a renewal option</description>
</item>
<item>
<title>Algernon Announces Additional Increase to Private Placement Financing to $858,000 and Final Closing of the Financing</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-additional-increase-private-210100902</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-additional-increase-private-210100902</guid>
<pubDate>Wed, 31 Dec 2025 21:01:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces an increase to its non-brokered private placement financing (the “Offering”), previously announced on November 6, 2025, to $858,000 and the closing of the fourth and final tranche (the “Fourth Tranche”). Gross p</description>
</item>
<item>
<title>Algernon Announces Increase to Private Placement Financing to $750,000 and Close of Third Tranche</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-increase-private-placement-210100165</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-increase-private-placement-210100165</guid>
<pubDate>Tue, 23 Dec 2025 21:01:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces an increase to its non-brokered private placement financing, previously announced on November 6, 2025, to $750,000 and the closing of the third tranche (the “Third Tranche”). Gross proceeds from the Third Tranch</description>
</item>
<item>
<title>Algernon Closes Second Tranche of Private Placement Financing</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-closes-second-tranche-private-005100385</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-closes-second-tranche-private-005100385</guid>
<pubDate>Sat, 29 Nov 2025 00:51:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces the closing of the second tranche (the “Second Tranche”) of its non-brokered private placement (the “Offering”), previously announced on November 6, 2025, with the first tranche closed on November 14, 2025. Gros</description>
</item>
<item>
<title>Algernon Health and American Molecular Imaging Announce Strategic Business and USD $500K Investment Agreement</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-health-american-molecular-imaging-120000985</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-health-american-molecular-imaging-120000985</guid>
<pubDate>Mon, 17 Nov 2025 12:00:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, and American Molecular Imaging (AMI), one of the leading radiology reading services providers in the U.S., are pleased to announce that they have entered into a strategic business and investment agreement (the “Agreement”</description>
</item>
<item>
<title>Algernon Closes First Tranche of its Recently Announced Private Placement Financing</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-closes-first-tranche-recently-005500834</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-closes-first-tranche-recently-005500834</guid>
<pubDate>Sat, 15 Nov 2025 00:55:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces the closing of the first tranche (the “First Tranche”) of its non-brokered private placement (the “Offering”), previously announced on November 6, 2025. Gross proceeds from the First Tranche totaled CAD $177,000</description>
</item>
<item>
<title>Algernon Health Announces Private Placement</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-health-announces-private-placement-120400184</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-health-announces-private-placement-120400184</guid>
<pubDate>Thu, 06 Nov 2025 12:04:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce a non-brokered private placement for gross proceeds of $500,000 (the “Offering”) of units (the “Units”) at an issue price of $0.07 per Unit. Each Unit will consist of one Class A common share in the capital of the Company (a “Common Share”) and one-half Common Share purchase warrant (a</description>
</item>
<item>
<title>Algernon Pharmaceuticals Completes Name Change to Algernon Health</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-pharmaceuticals-completes-name-change-110000756</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-pharmaceuticals-completes-name-change-110000756</guid>
<pubDate>Wed, 15 Oct 2025 11:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it has completed its previously announced name change to Algernon Health Inc. The Company’s common shares will begin trading under the new name on the CSE at market-open on Monday, October 20, 2025. The common shares will trade under the new name with a new CUSIP number, but the stock s</description>
</item>
<item>
<title>Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer’s Detection</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-cad-4-million-110000103</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-cad-4-million-110000103</guid>
<pubDate>Thu, 25 Sep 2025 11:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it has signed a definitive equipment order and financing agreement with Catalyst MedTech for the provision of four, U.S. FDA cleared Oncovision CareMiBrain™ brain-specific, Positron Emission Tomography (PET) scanner systems to be utilized in four planned Algernon neuroimaging medical c</description>
</item>
<item>
<title>Algernon Announces Preferred Share Class Approved at Annual and Special Meeting</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-preferred-share-class-203900684</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-preferred-share-class-203900684</guid>
<pubDate>Fri, 19 Sep 2025 20:39:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces the voting results at its annual and special meeting of shareholders held earlier today (the "Meeting") including an ordinary resolution (the “Resolution”) to approve an alteration to the Company’s authorized share structure and Articles, to include an unlimited number of Preferred Shares,</description>
</item>
<item>
<title>Algernon Pharmaceuticals Announces Name Change to Algernon Health</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-pharmaceuticals-announces-name-change-110000554</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-pharmaceuticals-announces-name-change-110000554</guid>
<pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it is changing its name to Algernon Health. The planned name change reflects the Company’s recent announcement that it will be focusing on the Alzheimer’s Disease (AD) diagnostic market with plans to establish specialized neuroimaging clinics across North America as its lead program. T</description>
</item>
<item>
<title>Algernon Announces Closing of the Private Placement Financing</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-closing-private-placement-210200593</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-closing-private-placement-210200593</guid>
<pubDate>Thu, 24 Jul 2025 21:02:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, announces the closing of a second tranche (the “Second Tranche”) of its non-brokered private placement (the “Offering”), previously announced on May 27, 2025, and with updated</description>
</item>
<item>
<title>Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-amended-terms-private-212900786</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-amended-terms-private-212900786</guid>
<pubDate>Mon, 30 Jun 2025 21:29:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is announcing amended pricing and warrant terms for its non-brokered private placement for gross proceeds of $1,000,000 (the “Offering”) of units of common shares (the “Common</description>
</item>
<item>
<title>Algernon Announces $1M Private Placement</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-1m-private-placement-110000941</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-1m-private-placement-110000941</guid>
<pubDate>Tue, 27 May 2025 11:00:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce a non-brokered private placement for gross proceeds of $1,000,000 (the “Offering”) of units of common shares (the “Common Units”) at an issue price of $0.</description>
</item>
<item>
<title>Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-closes-nobrainer-imaging-centers-005000825</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-closes-nobrainer-imaging-centers-005000825</guid>
<pubDate>Fri, 23 May 2025 00:50:00 GMT</pubDate>
<description>Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has closed the acquisition to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers, Inc. VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug deve</description>
</item>
<item>
<title>Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-acquire-nobrainer-imaging-centers-110000055</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-acquire-nobrainer-imaging-centers-110000055</guid>
<pubDate>Tue, 13 May 2025 11:00:00 GMT</pubDate>
<description>First Clinic Targeted to Open Q4, 2025 in the U.S.VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has entered into share exchange agreements to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers, Inc. (“NIC”) (the “Transaction”). The Transaction moves Algernon</description>
</item>
<item>
<title>Algernon Announces Warrant Extension</title>
<link>https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-warrant-extension-114700989</link>
<guid isPermaLink="true">https://6ix.com/company/algernon-pharmaceuticals-inc/news/algernon-announces-warrant-extension-114700989</guid>
<pubDate>Mon, 05 May 2025 11:47:00 GMT</pubDate>
<description>THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces that it has extended the expiry date of an aggregate of 4,752,969 outstanding warrants (the “2023 Warrants”). The 2023 Warrants were issued in connection wi</description>
</item>
</channel>
</rss>